The most common KMT2A fusion partners in AML patients include AF9 (MLLT3), AF10 (MLLT10), KMT2A-PTDs, ELL, AF6 (AFDN), ENL (MLLT1), and MLLT11 (Table 1) [12]. The gene discussed is ELL; the disease is acute myeloid leukemia.